Probatebeta
Company

Velicept Therapeutics

As of the edition of 20 October 2026, Velicept Therapeutics runs 1 drug; it is on route A at 1 target and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Family history

Velicept Therapeutics was bankrupt in 2025.

  • Velicept Therapeutics, Inc.: bankrupt in 2025

Drugs by status

StatusCount
Went quiet1
Total1

Where it needs a new molecule

Route A at 1 target, route B at 0 targets.

Three of its 1 rows, by target and route
TargetRoute
ADRB3 Beta-3 adrenergic receptorRoute A

All 1 row on route A or B

In the product

1 company-target row on route A or B; 0 are not shown here, and no score is.

See all 1 targets where Velicept Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.

Where its trials are

  • Pregnancy and women's health: 3 trials led
  • Urinary and reproductive: 3 trials led

Other companies active in pregnancy and women's health